Atropine in topical formulations for the management of anterior and posterior segment ocular diseases

References

• Lakstygal AM, Kolesnikova TO, Khatsko SL, et al. DARK classics in chemical neuroscience: atropine, scopolamine, and other anticholinergic deliriant hallucinogens. ACS Chem Neurosci. 2019;10(5):2144–2159.
   PubMed Web of Science ®Google Scholar
• Grynkiewicz G, Gadzikowska M. Tropane alkaloids as medicinally useful natural products and their synthetic derivatives as new drugs. Pharmacol Rep. 2008;60(4):439–463.
   PubMed Web of Science ®Google Scholar
• Broadley KJ, Kelly DR. Muscarinic receptor agonists and antagonists. Molecules. 2001;6(3):142–193.
   Web of Science ®Google Scholar
• Kanto J, Klotz U. Pharmacokinetic implications for the clinical use of atropine, scopolamine and glycopyrrolate. Acta Anaesthesiol Scand. 1988;32(2):69–78.
   PubMed Web of Science ®Google Scholar
• Wang LZ, Syn N, Li S, et al. The penetration and distribution of topical atropine in animal ocular tissues. Acta Ophthalmol. 2019;97(2):e238–e247.
   PubMed Web of Science ®Google Scholar
• Tran HDM, Tran YH, Tran TD, et al. A review of myopia control with atropine. J Ocul Pharmacol Ther. 2018;34(5):374–379.
   PubMed Web of Science ®Google Scholar
• McBrien NA, Stell WK, Carr B. How does atropine exert its anti-myopia effects? Ophtalmic. Physiol Opt. 2013;33(3):373–378.
   PubMed Web of Science ®Google Scholar
• Rachana PB, Sequeira J. Effect of intramuscular atropine sulphate and glycopyrrolate on heart rate and salivary secretion in patients undergoing minor oral surgical procedure. CUREUS. 2020;12(11):e11780.
   PubMed Web of Science ®Google Scholar
• Ittichaikulthol W, Pisitsak C, Wirachpisit N, et al. A comparison of the combination of atropine and glycopyrrolate with atropine alone for the reversal of muscle relaxant. J Med Assoc Thai. 2014;97(7):705–709.
   PubMedGoogle Scholar
• Geller RJ, Lopez GP, Cutler S, et al. Atropine availability as an antidote for nerve agent casualties: validated rapid reformulation of high-concentration atropine from bulk powder. Ann Emerg Med. 2003;41(4):453–456.
   PubMed Web of Science ®Google Scholar
• Smulyan H. The beat goes on: the story of five ageless cardiac drugs. Am J Med Sci. 2018;356:441–450.
   PubMed Web of Science ®Google Scholar
• Drugs.com [Internet]. Atropine side effects. [cited 2021 Mar 31]. Available from: https://www.drugs.com/sfx/atropine-side-effects.html
   Google Scholar
• Lahdes K, Kaila T, Huupponen R, et al. Systemic absorption of topically applied ocular atropine. Clin Pharmacol Ther. 1988;44(3):310–314.
   PubMed Web of Science ®Google Scholar
• North RV, Kelly ME. A review of the uses and adverse effects of topical administration of atropine. Ophthalmic Physiol Opt. 1987;7(2):109–114.
   PubMed Web of Science ®Google Scholar
• Ali-Melkkila T, Kanto J, Iisalo E. Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand. 1993;37(7):633–642.
   PubMed Web of Science ®Google Scholar
• Ramsay E, Ruponen M, Picardat T, et al. Impact of chemical structure on conjunctival drug permeability: adopting porcine conjunctiva and cassette dosing for construction of in silico model. J Pharm Sci. 2017;106(9):2463–2471.
   PubMed Web of Science ®Google Scholar
• Armenian P, Campagne D, Stroh G, et al. Hot and cold drugs: national park service medication stability at the extremes of temperature. Prehosp Emerg Care. 2017;21(3):378–385.
   PubMed Web of Science ®Google Scholar
• Berton B, Chennell P, Yessaad M, et al. Stability of ophthalmic atropine solutions for child myopia control. Pharmaceutics. 2020;12(8):781.
   Web of Science ®Google Scholar
• Donnelly RF, Corman C. Physical compatibility and chemical stability of a concentrated solution of atropine sulfate (2 mg/mL) for use as an antidote in nerve agent casualties. Int J Pharm Compound. 2008;12:550–552.
   PubMedGoogle Scholar
• Afsar A, Bajwa JA. Determination of best regime for administration of atropine eye drops for cycloplegia. Adv Ophthalmol Vis Syst. 2017;6:42–45.
   Google Scholar
• Wakayama A, Nishina S, Miki A, et al. Incidence of side effects of topical atropine sulfate and cyclopentolate hydrochloride for cycloplegia in Japanese children: a multicenter study. Jpn J Ophthalmol. 2018;62(5):531–536.
   PubMed Web of Science ®Google Scholar
• Siurana JM, Akel G, Cavero L, et al. Is treatment with atropine 0.01% eye drops safe to prevent the progression of childhood myopia? Arch Dis Child. 2019;104(3):428.
   Google Scholar
• Leblanc B, Jezequel S, Davies T, et al. Binding of drugs to eye melanin is not predictive of ocular toxicity. Regul Toxicol Pharmacol. 1998;28(2):124–132.
   PubMed Web of Science ®Google Scholar
• Agrahari V, Mandal A, Agrahari V, et al. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016;6(6):735–754.
   PubMed Web of Science ®Google Scholar
• Cristaldi M, Olivieri M, Pezzino S, et al. Atropine differentially modulates ECM production by ocular fibroblasts, and its ocular surface toxicity is blunted by colostrum. Biomedicines. 2020;8(4):78.
   Web of Science ®Google Scholar
• Wen Q, Fan TJ, Tian CL. Cytotoxicity of atropine to human corneal endothelial cells by inducing mitochondrion-dependent apoptosis. Exp Biol Med. 2016;241(13):1457–1465.
   PubMed Web of Science ®Google Scholar
• Argikar UA, Dumouchel JL, Kramlinger VM, et al. Do we need to study metabolism and distribution in the eye: why, when, and are we there yet? J Pharm Sci. 2017;106(9):2276–2281.
   PubMed Web of Science ®Google Scholar
• Lee J, Pelis RM. Drug transport by the blood-aqueous humor barrier of the eye. Drug Metab Dispos. 2016;44(10):1675–1681.
   PubMed Web of Science ®Google Scholar
• Castro-Balado A, Mondelo-García C, González-Barcia M, et al. Ocular bio-distribution studies using molecular imaging. Pharmaceutics. 2019;237(11):1–20.
   Google Scholar
• Dahlin A, Geier E, Stocker SL, et al. Gene expression profiling of transporters in the solute carrier and ATP-binding cassette superfamilies in human eye substructures. Mol Pharm. 2013;10(2):650–663.
   PubMedGoogle Scholar
• Bévalot F, Cartiser N, Bottinelli C, et al. Correlation of bile and vitreous humor concentrations with blood drug concentrations for forensic interpretation: a comparative study between animal experimental and human postmortem data. Forensic Toxicol. 2015;33(1):131–140.
   Web of Science ®Google Scholar
• Farkouh A, Frigo P, Czejka M. Systemic side effects of eye drops: a pharmacokinetic perspective. Clin Ophtalmol. 2016;10:2433–2441.
   PubMed Web of Science ®Google Scholar
• Short BG. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol Pathol. 2008;36(1):49–62.
   PubMed Web of Science ®Google Scholar
• Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Revs. 2006;58(11):1131–1135.
   PubMed Web of Science ®Google Scholar
• Bucolo C, Drago F, Salomone S. Ocular drug delivery: a clue from nanotechnology. Front Pharmacol. 2012;3:188.
   PubMed Web of Science ®Google Scholar
• Toropainen E, Ranta VP, Vellonen KS, et al. Paracellular and passive transcellular permeability in immortalized human corneal epithelial cell culture model. Eur J Pharm Sci. 2003;20(1):99–106.
   PubMed Web of Science ®Google Scholar
• Mori N, Mochizuki T, Yamazaki F, et al. MALDI imaging mass spectrometry revealed atropine distribution in the ocular tissues and its transit from anterior to posterior regions in the whole-eye of rabbit after topical administration. PLoS ONE. 2019;14(1):e0211376.
   PubMed Web of Science ®Google Scholar
• Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87(12):1479–1488.
   PubMed Web of Science ®Google Scholar
• Shen M, Li J, Wang J, et al. Upper and lower tear menisci in the diagnosis of dry eye. Investig Ophthalmol Vis Sci. 2009;50:722–2726.
   Web of Science ®Google Scholar
• Kaila T, Korte JM, Saari KM. Systemic bioavailability of ocularly applied 1% atropine eyedrops. Acta Ophthalmol Scand. 1999;77(2):193–196.
   PubMedGoogle Scholar
• Salazar M, Patil PN. An explanation for the long duration of mydriatic effect of atropine in eye. Invest Ophthalmol Vis Sci. 1976;15:671–673.
   Web of Science ®Google Scholar
• Gore A. Broad spectrum treatment for ocular insult induced by organophosphate chemical warfare agents. Toxicol Sci. 2020;177(1):1–10.
   PubMed Web of Science ®Google Scholar
• Agrawal RV, Murthy S, Sagwan V, et al. Current approach in diagnosis and management of anterior uveitis. Indian J Ophtalmol. 2010;58(1):11–19.
   PubMed Web of Science ®Google Scholar
• Bajoria SK, Biswas J. Recent approach in diagnosis and management of anterior uveitis. J Clin Ophthalmol Res. 2018;6:36–41.
   Google Scholar
• Tantou A, Konstas AG, Kozeis N, et al. Update on the treatment of uveitis in patients with juvenile idiopathic arthritis: a review. Adv Ther. 2017;34(12):2558–2565.
   PubMed Web of Science ®Google Scholar
• Hussaindeen JR, Mani R, Agarkar S, et al. Acute adult onset comitant esotropia associated with accommodative spasm. Optom Vis Sci. 2014;91(4):46–51.
   Web of Science ®Google Scholar
• Hyndman J. Spasm of the near reflex: literature review and proposed management strategy. J Binocul Vis Ocul Motil. 2018;68(3):78–86.
   PubMedGoogle Scholar
• Lind T, Atkinson S, Marsh JD. Diagnosis of accommodative spasm aided by handheld photoscreener. J Binocul Vis Ocul Motil. 2020;70(1):37–39.
   PubMedGoogle Scholar
• Satgunam P. Relieving accommodative spasm: two case reports. Optom Vis Sci. 2018;6(5):207–212.
   Google Scholar
• Amescua G, Miller D, Alfonso E. What is causing the corneal ulcer? Management strategies for unresponsive corneal ulceration. Eye. 2012;26(2):228–236.
   PubMed Web of Science ®Google Scholar
• Garg P, Rao GN. Corneal ulcer: diagnosis and management. Community Eye Health. 1999;12(30):21–23.
   PubMedGoogle Scholar
• Shoshany TN, Michalak S, Staffa SJ, et al. Effect of primary occlusion therapy in asymmetric, bilateral amblyopia. Am J Ophthalmol. 2020;211:87–93.
   PubMed Web of Science ®Google Scholar
• Jefferis JM, Connor AJ, Clarke MP. Amblyopia. BMJ. 2015;351(nov12 1):h5811.
   PubMedGoogle Scholar
• Gopal SKS, Kelkar J, Kelkar A, et al. Simplified updates on the pathophysiology and recent developments in the treatment of amblyopia: a review. Indian J Ophthalmol. 2019;67(9):1392–1399.
   PubMed Web of Science ®Google Scholar
• Li, Li Y, Sun H, et al. Efficacy of interventions for amblyopia: a systematic review and network metaanalysis. BMC Ophthalmol. 2020;20(1):203. .
   PubMed Web of Science ®Google Scholar
• Park SH. Current management of childhood amblyopia. Korean J Ophthalmol. 2019;33(6):557–568.
   PubMedGoogle Scholar
• Li T, Qureshi R, Taylor K. Conventional occlusion versus pharmacologic penalization for amblyopia (Review). Cochrane Database Syst Rev. 2019;8:CD006460.
   PubMedGoogle Scholar
• Osborne DC, Greenhalgh KM, Evans MJE, et al. Atropine penalization versus occlusion therapies for unilateral amblyopia after the critical period of visual development: a systematic review. Ophthalmol Ther. 2018;7(2):323–332.
   PubMed Web of Science ®Google Scholar
• Wang J. Compliance and patching and amblyopia treatments. Vision Res. 2015;114:31–40.
   PubMed Web of Science ®Google Scholar
• Kraus CL, Culican SM. New advances in amblyopia therapy I: binocular therapies and pharmacologic augmentation. Br J Ophthalmol. 2018;102(11):1492–1496.
   PubMed Web of Science ®Google Scholar
• Repka MX, Kraker RT, Holmes JM, et al. Pediatric Eye Disease Investigator Group. A randomized trial of atropine versus patching for treatment of moderate amblyopia: follow-up at 15 years of age. JAMA Ophthalmol. 2014;132(7):799–805.
   PubMed Web of Science ®Google Scholar
• Haridas A, Syrimi M, Al-Ahmar B, et al. Intraoperative floppy iris syndrome (IFIS) in patients receiving tamsulosin or doxazosin- a UK-based comparison of incidence and complication rates. Graefes Arch Clin Exp Ophthalmol. 2013;251(6):1541–1545.
   PubMed Web of Science ®Google Scholar
• Esen F, Erdagi Bulutu A, Toker E. Efficacy and safety of low-concentration, bisulphite-containing, intracameral epinephrine and topical atropine treatments for the prevention of intraoperative floppy iris syndrome. Cutan Ocul Toxicol. 2018;37(3):286–290.
   PubMed Web of Science ®Google Scholar
• Pérez Silguero D, Ramallo Fariña Y, Pérez Silguero MA, et al. Comparison of the effectiveness of two different pharmacologic approaches to prevent intraoperative floppy iris syndrome. Arch Soc Esp Oftalmol. 2009;84(11):549–556.
   PubMedGoogle Scholar
• Bendel RE, Phillips MB. Preoperative use of atropine to prevent intraoperative floppy-iris syndrome in patients taking tamsulosin. J Cataract Refract Surg. 2006;32(10):1603–1605.
   PubMed Web of Science ®Google Scholar
• Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005;31(4):664–673.
   PubMed Web of Science ®Google Scholar
• Masket S, Belani S. Combined preoperative topical atropine sulfate 1% and intracameral nonpreserved epinephrine hydrochloride 1:2500 for management of intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2007;33(4):580–582.
   PubMed Web of Science ®Google Scholar
• Flitcroft DI, He M, Jonas JB, et al. IMI – defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci. 2019;60(3):M20–M30.
   PubMed Web of Science ®Google Scholar
• Tkatchenko TV, Tkatchenjo AV. Pharmacogenomic approach to antimyopia drug development: pathways lead the way. Trends Pharmacol Sci. 2019;40(11):833–852.
   PubMed Web of Science ®Google Scholar
• Stone RA, Pardue MT, Iuvone PM, et al. Pharmacology of myopia and potential role for intrinsic retinal circadian rhythms. Exp Eye Res. 2013;114:35–47.
   PubMed Web of Science ®Google Scholar
• Cooper J, Tkatchenko A. A review of current concepts of the etiology and treatment of myopia. Eye Contact Lens. 2018;44(4):231–247.
   PubMed Web of Science ®Google Scholar
• World Health Organization [Internet]. [cited 2021 Mar 31]. Available from: https://www.who.int/publications/i/item/world-report-on-vision.
   Google Scholar
• De Jong PTVM. Myopia: its historical context. Br J Ophthalmol. 2018;102(8):1021–1027.
   PubMed Web of Science ®Google Scholar
• Hughes RPJ, Vincent SJ, Read SA, et al. Higher order aberrations, refractive error development and myopia control: a review. Clin Exp Optom. 2020;103(1):68–85.
   PubMed Web of Science ®Google Scholar
• Feldkaemper M, Schaeffel F. An updated view on the role of dopamine in myopia. Exp Eye Res. 2013;114:106–119.
   PubMed Web of Science ®Google Scholar
• Truong HT, Cottriall CL, Gentle A, et al. Pirezepine affects scleral metabolic changes in myopia through a non-toxic mechanism. Exp Eye Res. 2002;74(1):103–111.
   PubMed Web of Science ®Google Scholar
• Harper AR, Summers JA. The dynamic sclera: extracellular matrix remodelling in normal ocular growth and myopia development. Exp Eye Res. 2015;133:100–111.
   PubMed Web of Science ®Google Scholar
• Vagge A, Ferro Desideri L, Nucci P, et al. Prevention of progression in myopia: a systematic review. Diseases. 2018;6(4):1–25.
   Google Scholar
• Vutipongsatorn K, Yokoi T, Ohno-Matsui K. Current and emerging pharmaceutical interventions for myopia. Br J Ophthalmol. 2019;103(11):1539–1548.
   PubMed Web of Science ®Google Scholar
• Schwahn HN, Kaymak H, Schaeffel F. Effects of atropine on refractive development, dopamine release, and slow retinal potentials in the chick. Vis Neurosci. 2000;17(2):165–176.
   PubMed Web of Science ®Google Scholar
• Anders LM, Heinrich SP, Lagrèze WA, et al. Little effect of 0.01% atropine eye drops as used in myopia prevention on the pattern electroretinogram. Doc Ophtalmol. 2019;138(2):85–89.
   PubMed Web of Science ®Google Scholar
• Carr BJ, Stel WK. Nitric oxide (NO) mediates the inhibition of form-deprivation myopia by atropine in chicks. Sci Rep. 2016;6(1):1–13.
   PubMedGoogle Scholar
• Garcia Del Valle AM, Blázquez V, Gros-Otero J, et al. Efficacy and safety of a soft contact lens to control myopia progression. Clin Exp Optom. 2021;104(1):14–21.
   PubMed Web of Science ®Google Scholar
• Novack GD. Drug to prevent pediatric myopia: what would it take? Eye Contact Lens. 2018;44(4):220–223.
   PubMed Web of Science ®Google Scholar
• Wan L, Wei CC, Chen CS, et al. The synergistic effects of orthokeratology and atropine in slowing the progression of myopia. J Clin Med. 2018;7(9):259.
   Web of Science ®Google Scholar
• Fang PC, Chung MY, Yu HJ, et al. Prevention of myopia onset with 0.025% atropine in premyopic children. J Ocul Pharmacol Ther. 2010;26(4):341–345.
   PubMed Web of Science ®Google Scholar
• Upadhyay A, Beuerman RW. Biological mechanisms of atropine control of myopia. Eye Contact Lens. 2020;46(3):129–135.
   PubMed Web of Science ®Google Scholar
• Cooper J, Eisenberg N, Schulman E, et al. Maximum atropine dose without clinical signs or symptoms. Optom Vis Sci. 2013;90(12):467–472.
   Web of Science ®Google Scholar
• Ho MC, Hsieh YT, Shen EP, et al. Short‑term refractive and ocular parameter changes after topical atropine. Taiwan J Ophthalmol. 2020;10(2):111–115.
   PubMedGoogle Scholar
• Cheng J, Yang Y, Kong X, et al. The effect of 0.01% atropine eye drops on the ocular surface in children for the control of myopia—the primary results from a six-month prospective study. Ther Clin Risk Manag. 2020;16:735–740.
   PubMed Web of Science ®Google Scholar
• Gong Q, Janowski M, Luo M, et al. Efficacy and adverse effects of atropine in childhood myopia A meta-analysis. JAMA Ophthalmol. 2017;135(6):624–630.
   PubMed Web of Science ®Google Scholar
• Loughman J, Flitcroft DI. The acceptability and visual impact of 0.01% atropine in Caucasian population. Br J Ophtalmol. 2016;100(11):1525–1529.
   PubMed Web of Science ®Google Scholar
• Chan LW, Hsieh YT, Hsu WC, et al. Optic disc parameters of myopic children with atropine treatment. Curr Eye Res. 2017;42(12):1614–1619.
   PubMed Web of Science ®Google Scholar
• Lee CY, Sun CC, Lin YF, et al. Effects of topical atropine on intraocular pressure and myopia progression: a prospective comparative study. BMC Ophthalmol. 2016;16(1):114.
   PubMedGoogle Scholar
• Yu TC, Wu TE, Wang YS, et al. A STROBE-compliant case–control studyEffects of cumulative doses of topical atropine on intraocular pressure and myopia progression. Medicine (Baltimore). 2020;99(48):e22745.
   PubMed Web of Science ®Google Scholar
• Liu YM, Xie P. The safety of orthokeratology - a systematic review. Eye Contact Lens. 2016;42(1):35–42.
   PubMed Web of Science ®Google Scholar
• Lipson MJ, Brooks MM, Koffler BH. The role of orthokeratology in myopia control: a review. Eye Contact Lens. 2018;44(4):224–230.
   PubMed Web of Science ®Google Scholar
• Kinoshita N, Konno Y, Hamada N, et al. Additive effects of orthokeratology and atropine 0.01% ophthalmic solution in slowing axial elongation in children with myopia: first years results. Jpn J Ophthalmol. 2018;62(5):544–553. .
   PubMed Web of Science ®Google Scholar
• Dumouchel JL, Chemuturi N, Milton MN, et al. Models and approaches describing metabolism, transport and toxicity of drugs administered by the ocular route. Drug Metab Dispos. 2018;46(11):1670–1683. .
   PubMed Web of Science ®Google Scholar
• El Hoffy NM, Azim EAA, Hathout RM, et al. Glaucoma: management and future perspectives for nanotechnology-based treatment modalities. Eur J Pharm Sci. 2021;158:105648.
   PubMed Web of Science ®Google Scholar
• Chetoni P, Burgalassi S, Monti D, et al. Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: pharmacokinetic studies on rabbits. Eur J Pharm Biopharm. 2016;109:214–223.
   PubMed Web of Science ®Google Scholar
• Addo RT, Yeboah KG, Siwale RC, et al. Formulation and characterization of atropine sulfate in albumin-chitosan microparticles for in vivo ocular drug delivery. J Pharm Sci. 2015;104(5):1677–1690. .
   PubMed Web of Science ®Google Scholar
• Järvinen K, Järvinen T, Urtti A. Ocular absorption following topical delivery. Adv Drug Deliv Revs. 1995;16(1):3–19.
   Web of Science ®Google Scholar
• Rathore KS, Nema RK. An insight into ophthalmic drug delivery system. Int J Pharm Sci Drug Res. 2009;1(1):1–5.
   Google Scholar
• Meisner D, Pringle J, Mezei M. Liposomal ophthalmic drug delivery 3. pharmacodynamic and biodisposition studies of atropine. Int J Pharm. 1989;55:105–113.
   Web of Science ®Google Scholar
• Verestiuc L, Nastasescu O, Barbu E, et al. Functionalized chitosan/NIPAM (HEMA) hybrid polymer networks as inserts for ocular drug delivery: synthesis, in vitro assessment, and in vivo evaluation. J Biomed Mater Res A. 2006;77A(4):726–753.
   Web of Science ®Google Scholar
• Pijls RT, Koole LH, Hanssen HH, et al. Flexible coils with a drug-releasing hydrophilic coating: a new platform for controlled delivery of drugs to the eye? J Bioact Compat Polym. 2004;19(4):267–285.
   Web of Science ®Google Scholar
• Gonzalez-Chomón C, Concheiro A, Alvarez-Lorenzo C. Soft contact lenses for controlled ocular delivery: 50 years in the making. Ther Deliv. 2013;4(9):1141–1161.
   PubMedGoogle Scholar
• Alvarez-Lorenzo C, Anguiano-Igea S, Varela-Garcia A, et al. Bioinspired hydrogels for drug-eluting contact lenses. Acta Biomater. 2019;84:49–62.
   PubMed Web of Science ®Google Scholar
• Lanier OL, Christopher KG, Macoon RM, et al. Commercialization challenges for drug eluting contact lenses. Expert Opin Drug Deliv. 2020;17(8):1133–1149.
   PubMed Web of Science ®Google Scholar
• Glisoni RJ, Garcia-Fernandez MJ, Pino M, et al. Beta-cyclodextrin hydrogels for the ocular release of antibacterial thiosemicarbazones. Carbohydr Polym. 2013;93(2):449–457.
   PubMed Web of Science ®Google Scholar
• Topete A, Oliveira AS, Fernandes A, et al. Improving sustained drug delivery from ophthalmic lens materials through the control of temperature and time of loading. Eur J Pharm Sci. 2018;117:107–117.
   PubMed Web of Science ®Google Scholar
• Li CC, Chauhan A. Modelling ophthalmic drug delivery by soaked contact lenses. Ind Eng Chem Res. 2006;45(10):3718–3734.
   Web of Science ®Google Scholar
• Dixon P, Ghosh T, Mondal K, et al. Controlled delivery of pirfenidone through vitamin E-loaded contact lens ameliorates corneal inflammation. Drug Deliv Transl Res. 2018;8(5):1114–1126.
   PubMed Web of Science ®Google Scholar
• Tieppo A, White CJ, Paine AC, et al. Sustained in vivo release from imprinted therapeutic contact lenses. J Control Release. 2012;157(3):391–397.
   PubMed Web of Science ®Google Scholar
• Desai AR, Maulvi FA, Desai DM, et al. Multiple drug delivery from the drug-implants-laden silicone contact lens: addressing the issue of burst drug release. Mater Sci Eng C. 2020;112:110885.
   PubMed Web of Science ®Google Scholar
• Musgrave CSA, Fang F. Contact lens materials: a materials science perspective. Materials. 2019;12(261):1–36.
   Google Scholar
• Choi JH, Li Y, Jin R, et al. The efficiency of cyclosporine a-eluting contact lenses for the treatment of dry eye. Curr Eye Res. 2019;44(5):486–496.
   PubMed Web of Science ®Google Scholar
• Braga MEM, Costa VP, Pereira MJT, et al. Effects of operational conditions on the supercritical solvent impregnation of acetazolamide in Balafilcon A commercial contact lenses. Int J Pharm. 2011;420(2):231–243.
   PubMed Web of Science ®Google Scholar
• Ubani-Ukoma U, Gibson D, Schultz G, et al. Evaluating the potential of drug eluting contact lenses for treatment of bacterial keratitis using an ex vivo corneal model. Int J Pharm. 2019;565:499–508.
   PubMed Web of Science ®Google Scholar
• Silva D, De Sousa HC, Gil MH, et al. Diclofenac sustained release from sterilised soft contact lens materials using an optimised layer-by-layer coating. Int J Pharm. 2020;585:119506.
   PubMed Web of Science ®Google Scholar
• Hui A, Bagrowicz-Cieslak M, Phan C, et al. In vitro release of two antimuscarinic drugs from soft contact lenses. Clin Ophthalmol. 2017;11:1657–1665.
   PubMed Web of Science ®Google Scholar
• Lasowski F, Sheardown H. Atropine and roscovitine release from model silicone hydrogels. Optom Vis Sci. 2016;93(4):404–411.
   PubMed Web of Science ®Google Scholar